Kezar Life Sciences, Inc. Quality Score

KZR

⊜ Compare

Quality20

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Growth

Cash Flow Growth

0/100

Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution

100/100

-89.1%

Shrinking >2%, active buybacks

Capital Structure

100/100

-$65M

Net cash position, no leverage concern

2022

$277M

$21.0M

2023

$201M

$19.0M

2024

$132M

$16.0M

2025

$72.0M

$2.00M

TTM

$66.0M

$1.00M

CashDebt

Return on Capital

0/100

-46.0%

Below 8%, may not cover cost of capital

Customize WeightsPremiumAdjust metric weights to match your investment style.Upgrade

SourceQuality score computed from the 10-Q filed 7 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 6 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with KZR

CompareIntrinsic value

NAMSNewAmsterdam Pharma Co. N.V.

$20.93+5.18%10

HCWBHCW Biologics Inc.

$1.08-6.09%15

ALMSAlumis Inc.

$6.55+0.77%10

ROIVRoivant Sciences Ltd

$38.23+6.08%16

ADAGAdagene Inc.

$2.41+2.55%25

COYACoya Therapeutics Inc.

$3.08-0.96%10

ABEOAbeona Therapeutics Inc.

$4.22-0.71%40

ACRSAclaris Therapeutics, Inc.

$3.68-1.60%10

Spot a number that looks wrong? Check it in KZR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KZR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.